The and similar weight-loss injections is threatening to upend the industry built around obesity in the US, hammering the valuations of companies that help treat weight-related conditions such as and sleep apnea.Novo Nordisk, the Denmark-based maker of diabetes drug Ozempic, is riding high after showed its weight-loss branding of the injection, Wegovy, also had a clear cardiovascular benefit.Shares of rival Eli Lilly, whose diabetes injection Mounjaro may be even more effective at slashing obesity, also surged on the news, which drugmakers hope will pave the way to make such injections a routine lifestyle treatment.
Load More
Load More